Cellectis - CLLS Enterprise Value-to-Sales Ratio

Public company logo of Cellectis S.A. (CLLS)

Cellectis S.A. (CLLS) is facing a liquidity shortage due to costly development efforts. However, diversification through unique gene editing for various types of cancer mitigates these risks. In-house manufacturing facilities minimize outsourcing, which supports the business's enterprise value-to-revenue ratio. The 152.25 metric indicates the status of market valuations, capturing the current trend shown on this chart.

Cellectis SA (CLLS): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Cellectis (CLLS)

Fundamental valuation:Cellectis SA (CLLS)
Core merchandise of cellectis.com

This indicator determines investment reliability by comparing the total enterprise value to the volume of generated revenue. The metric eliminates the impact of leverage, revealing the gap between market expectations and actual cash flows. Analyzing the EV/Sales ratio allows investors to filter out speculative noise from genuine growth. For Cellectis S.A. (CLLS), such a valuation is critical, as the market capitalization relies on the value of TALEN patents. Exclusive contracts with pharmaceutical behemoths provide the fundamental basis for current quotes.